Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I.

In order to study the effect of increased CD4 cell counts on the biology of hepatitis C virus (HCV), we analyzed the genetic variability of HCV generated over 8 y in eight human immunodeficiency virus-1 (HIV-1) and HCV co-infected patients. This was a retrospective study in which HIV patients were selected who had profound immune impairment evident over four years and were co-infected with HCV genotype 1 and who then went on highly active antiretroviral therapy (HAART). These patients achieved different degrees of immune reconstitution, measured as increased CD4 cell counts during a 4- to 8-y period, following initiation of HAART. HCV genetic variability was determined by measuring the genetic diversity (Hamming distance, HD), and complexity (number of viral variants) in plasma samples collected at yearly intervals just before and after the initiation of HAART. The parameters were assessed by molecular cloning and sequencing of a 575-bp fragment including the HCV envelope 1 and envelope 2 genes (E1/E2), containing the hypervariable region 1 (HVR1). significantly increased HVR1 genetic diversity was observed in analyzed samples where the patients' CD4 cell counts were > or =100 compared with CD4 cell counts <100. A significant increase in genetic diversity in HVR1 was detected in co-infected patients whose CD4 cell counts increased from <100 to >400 over a period of more than 4 y of HAART therapy. This was in contrast to a minimal increase in HCV genetic diversity of HVR1 occurring in patients whose CD4 cell counts failed to rise much over 200 over 7 y of follow up. Insertion and deletion of HCV genomic fragments in the E1/E2 region was documented in one patient who developed fulminant hepatitis C.

[1]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[2]  C. Cooper,et al.  Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection , 2004, AIDS.

[3]  D. Neau,et al.  Hepatitis C virus genetic variability in 52 human immunodeficiency virus‐coinfected patients , 2003, Journal of medical virology.

[4]  M. Holodniy,et al.  Impact of Highly Active Antiretroviral Therapy and Immunologic Status on Hepatitis C Virus Quasispecies Diversity in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients , 2003, Journal of Virology.

[5]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Meyer,et al.  Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. , 2002, The Journal of infectious diseases.

[7]  C. Katlama,et al.  Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.

[8]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[10]  R. Chapman,et al.  Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus , 1999, Hepatology.

[11]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[12]  Joseph P. Romano,et al.  Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma , 1997, Journal of clinical microbiology.

[13]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[14]  E. Tanzi,et al.  Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. , 1994, The New England journal of medicine.

[15]  Roger Williams,et al.  Virus‐induced autoimmunity in hepatitis C virus infections: A rare event , 1994, Journal of medical virology.

[16]  R. Koff,et al.  Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. , 1993, Archives of internal medicine.

[17]  R. Miller,et al.  Lack of protective immunity against reinfection with hepatitis C virus. , 1993, Science.

[18]  D. Thiele Implications of anti-hepatitis C reactivity in 'autoimmune' chronic active hepatitis. , 1990, Gastroenterology.

[19]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[20]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[21]  P. Plagemann,et al.  Hepatitis C virus , 2005, Archives of Virology.